Nepidermin

Drug Profile

Nepidermin

Alternative Names: DWP-401; Easyef; Recombinant human epidermal growth factor - Daewoong; rhEGF - Daewoong

Latest Information Update: 07 Oct 2015

Price : $50

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Growth factors; Skin disorder therapies
  • Mechanism of Action Epidermal growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diabetic foot ulcer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Alopecia; Diabetic foot ulcer; Wounds
  • Phase III Stomatitis

Most Recent Events

  • 05 Jun 2015 Phase-III development for Stomatitis is ongoing in South Korea
  • 03 Sep 2014 Launched for Wounds in Vietnam, Philippines and Thailand (Topical) prior to September 2014
  • 03 Sep 2014 Launched for Diabetic foot ulcer in Vietnam, Philippines and Thailand (Topical) prior to September 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top